Sam Brusco, Associate Editor11.01.23
BioSig has been awarded five new utility patents from the U.S. Patent and Trademark Office covering the company’s PURE EP digital signal processing technology.
BioSig chairman and CEO Kenneth Londoner told the press, “We are pleased to add five utility patent awards to our expanding intellectual property portfolio of more than 100 patents and patent applications in the U.S. and abroad. Our robust patent protection and well-constructed claims cover BioSig’s first mover advantage for our novel PURE EP Platform.”
These new patents bring the company’s totals to:
- U.S. Patent Application No. 16/543,061 was allowed on September 22, entitled “Systems and Methods To Display Cardiac Signals Based on a Signal Pattern.” The application describes and claims a computer method for viewing cardiac signals side by side and vertically stacked on top of each other, as a pattern is matched to one of the cardiac signals.
- U.S. Patent No. 11,737,699 granted on August 29, entitled “Systems and Methods for Performing Electrophysiology (EP) Signal Processing.” It describes and claims methods and systems for producing a clean unipolar signal.
- U.S. Patent No. 11,737,701 granted on August 29, entitled “Methods, Systems and Media For Reconstructing Bioelectric Lead Placement.” It describes and claims methods and systems for reconstructing electrode placement on a patient using artificial intelligence (AI).
- U.S. Patent 11,617,529 granted on April 4, entitled “Apparatus and Methods for Removing a Large-Signal Voltage Offset from a Biomedical Signal.” It claims a method for processing an electrical signal having a large differential voltage offset.
- U.S. Patent 11,617,530 granted on April 4, entitled “Apparatus and Methods for Removing a Large-Signal Voltage Offset from a Biomedical Signal.” It claims a system for the removal of noise in electrocardiogram (ECG) and intracardiac (IC) signals.
BioSig chairman and CEO Kenneth Londoner told the press, “We are pleased to add five utility patent awards to our expanding intellectual property portfolio of more than 100 patents and patent applications in the U.S. and abroad. Our robust patent protection and well-constructed claims cover BioSig’s first mover advantage for our novel PURE EP Platform.”
These new patents bring the company’s totals to:
- 35 issued and allowed utility patents
- 30 issued worldwide design patents
- 23 U.S. and foreign utility patent applications pending covering various aspects of the PURE EP Platform
- One allowed and one pending U.S. patent applications directed to AI
- Licenses to 11 patents and nine additional worldwide utility patent applications pending from Mayo Foundation for Medical Education and Research